Advances in minimally invasive facial rejuvenation

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 16, Issue 4, 2008, Pages 359-368

  Fedok, Fred G ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Botulinum toxin; Fillers; Hyaluronic acid; Rhytids; Wrinkles

Indexed keywords

ARTEFILL; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; COLLAGEN; COLLAGEN IMPLANT; ELEVESS; FAT; FIBREL; FILLER; HYALURONIC ACID; HYDROXYAPATITE; JUVEDERM; POLYLACTIC ACID; RADIESSE; UNCLASSIFIED DRUG; LACTIC ACID; POLYMER;

CHIN; DRUG APPROVAL; DRUG MECHANISM; DRY EYE; FACE; FOREHEAD; HEAD AND NECK MALFORMATION; HEMATOMA; HUMAN; LIP; MINIMALLY INVASIVE FACIAL REJUVENATION; MINIMALLY INVASIVE PROCEDURE; ORBIT; PAIN; PRIORITY JOURNAL; PTOSIS; REJUVENATION; REVIEW; SKIN DISEASE; SKIN IRRITATION; VISUAL DISORDER; COMPARATIVE STUDY; DRUG EFFECT; ESTHETICS; FACE MUSCLE; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; MINIMALLY INVASIVE SURGERY; PROSTHESES AND ORTHOSES; RHYTIDOPLASTY;

BOTULINUM TOXIN TYPE A; COLLAGEN; DURAPATITE; ESTHETICS; FACIAL MUSCLES; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRAMUSCULAR; LACTIC ACID; POLYMERS; PROSTHESES AND IMPLANTS; RHYTIDOPLASTY; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 52449118872     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e3283031c7d     Document Type: Review

References (83)

1. Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am 2007; 15:63-76; vii.
2. Lewis C. Botox cosmetic: a look at looking good. FDA Consumer Magazine; 2002.
3. Frueh BR, Musch DC. Treatment of facial spasm with botulinum toxin. An interim report. Ophthalmology 1986; 93:917-923.
4. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol 1984; 102:1464-1468.
5. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985; 103:347-350.
6. Savino PJ, Sergott RC, Bosley TM, Schatz NJ. Hemifacial spasm treated with botulinum A toxin injection. Arch Ophthalmol 1985; 103:1305-1306.
7. Berlin AJ, Cassen JH, DeNelsky G, et al. Benign essential blepharospasm treated with botulinum toxin. Cleve Clin J Med 1987; 54:421 -426.
8. Carruthers A. Botulinum toxin type A: history and current cosmetic use in the upper face. Dis Mon 2002; 48:299-322.
9. Sadick NS. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2400 and 3000 U for the treatment of glabellar wrinkles. Dermatol Surg 2003; 29:501 -507. (discussion 507).
10. Kim EJ, Ramirez AL, Reeck JB, Maas CS. The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconstr Surg 2003; 112:88S-93S. (discussion 94S-97S).
11. Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 2002; 126:459-467.
12. Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin 2004; 22:151 -158.
13. Blitzer A, Binder WJ. Cosmetic uses of botulinum neurotoxin type A: an overview. Arch Facial Plast Surg 2002; 4:214-220.
14. Blitzer A, Binder WJ, Aviv JE, et al. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997; 123:389-392.
15. Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993; 119:101 8-1022.
16. Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 2001; 111:218-226.
17. Carruthers JD, Lowe NJ, Menter MA, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112:1089-1098.
18. Matarasso SL, Matarasso A. 'M' marks the spot: update on treatment guidelines for botulinum toxin type A for the periocular area. Plast Reconstr Surg 2003; 112:1470-1472.
19. Carruthers A, Carruthers J. Botulinum toxin type A for the treatment of glabellar rhytides. Dermatol Clin 2004; 22:137-144.
20. Hatton MP, Rubin PA. A review of facial anatomy as it relates to the use of botulinum toxin. Int Ophthalmol Clin 2005; 45:39-47.
21. Carruthers J, Carruthers A. The use of botulinum toxin type A in the upper face. Facial Plast Surg Clin North Am 2006; 14:253-260.
22. Levy JL, Pons F, Jouve E. Management of the ageing eyebrow and forehead: an objective dose-response study with botulinum toxin. J Eur Acad Dermatol Venereol 2006; 20:711-716.
23. Maas CS. Botulinum neurotoxins and injectable fillers: minimally invasive management of the aging upper face. Facial Plast Surg Clin North Am 2006; 14:241 -245.
24. Dastoor SF, Misch CE, Wang HL Botulinum toxin (Botox) to enhance facial macroesthetics: a literature review. J Oral Implantol 2007; 33:164-171.
25. Maas CS. Botulinum neurotoxins and injectable fillers: minimally invasive management of the aging upper face. Otolaryngol Clin North Am 2007; 40:283-290.
26. Carruthers A, CarruthersJ,Cohen J. A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg 2003; 29:461-467.
27. Rzany B, Ascher B, Fratila A, et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142:320-326.
28. Redaelli A, Forte R. How to avoid brow ptosis after forehead treatment with botulinum toxin. J Cosmet Laser Ther 2003; 5:220-222.
29. Maas CS, Kim EJ. Temporal brow lift using botulinum toxin A: an update. Plast Reconstr Surg 2003; 112:109S-112S. (discussion 113S-114S).
30. Carruthers A, Carruthers J. Eyebrow height after botulinum toxin type A to the glabella. Dermatol Surg 2007; 33:S26-S31.
31. Chen AH, Frankel AS. Altering brow contour with botulinum toxin. Facial Plast Surg Clin North Am 2003; 11:457-464.
32. Foster JA, Proffer PL, Proffer LH, et al. Modifying brow position with botulinum toxin. Int Ophthalmol Clin 2005; 45:123-131.
33. Balikian RV, Zimbler MS. Primary and adjunctive uses of botulinum toxin type A in the periorbital region. Facial Plast Surg Clin North Am 2005; 13:583-590; vii.
34. Spiegel JH. Treatment of periorbital rhytids with botulinum toxin type A: maximizing safety and results. Arch Facial Plast Surg 2005; 7:198-202.
35. Lowe NJ, Yamauchi P. Cosmetic uses of botulinum toxins for lower aspects of the face and neck. Clin Dermatol 2004; 22:18-22.
36. Sposito MM. New indications for botulinum toxin type a in cosmetics: mouth and neck. Plast Reconstr Surg 2002; 110:601-611 (discussion 612-613).
37. Rzany B, Dill-Muller D, Grablowitz D, et al. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4103 treatments in 945 patients. Dermatol Surg 2007; 33:S18-25.
38. Ferreira MC, Salles AG, Gimenez R, Soares MF. Complications with the use of botulinum toxin type a in facial rejuvenation: report of 8 cases. Aesthetic Plast Surg 2004; 28:441 -444.
39. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 2004; 22:66-75.
40. Vartanian AJ, Dayan SH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am 2005; 13:1 -10.
41. Narins RS, Brandt FS, Lorenc ZP, et al. A randomized, multicenter study of the safety and efficacy of Dermicol-P35 and nonanimal-stabilized hyaluronic acid gel for the correction of nasolabial folds. Dermatol Surg 2007; 33(Suppl 2):S213-S221 (discussion S221).
42. Monheit GD, Coleman KM. Hyaluronic acid fillers. Dermatol Ther 2006; 19:141 -150.
43. Carruthers A, Carey W, De Lorenzi C, et al. Randomized, double-blind comparison of the efficacy of two hyaluronic acid derivatives, restylane perlane and hylaform, in the treatment of nasolabial folds. Dermatol Surg 2005; 31:1591 -1598 (discussion 1598).
44. Carruthers J, Klein AW, Carruthers A, et al. Safety and efficacy of nonanimal stabilized hyaluronic acid for improvement of mouth corners. Dermatol Surg 2005; 31:276-280.
45. Matarasso SL, Carruthers JD, Jewell ML. Consensus recommendations for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg 2006; 117:3S-34S (discussion 35S-43S).
46. Baumann LS, Shamban AT, Lupo MP, et al. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007; 33 (Suppl 2):S128-S135.
47. Beer K. A randomized, evaluator-blinded comparison of efficacy of hyaluronic acid gel and avian-sourced hylan B plus gel for correction of nasolabial folds. Dermatol Surg 2007; 33:928-936.
48. Hamilton MM, Hobgood T. Emerging trends and techniques in male aesthetic surgery. Facial Plast Surg 2005; 21:324-328.
49. Stupak HD, Moulthrop TH, Wheatley P, et al. Calcium hydroxylapatite gel (Radiesse) injection for the correction of postrhinoplasty contour deficiencies and asymmetries. Arch Facial Plast Surg 2007; 9:130-136.
50. Ahn MS. Calcium hydroxylapatite: Radiesse. Facial Plast Surg Clin North Am 2007; 15:85-90; vii.
51. Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006; 118:22S-30S. (discussion 31S-33S).
52. Jacovella PF, Peiretti CB, Cunille D, et al. Long-lasting results with hydro-xylapatite (Radiesse) facial filler. Plast Reconstr Surg 2006; 118:15S-21S.
53. Godin MS, Majmundar MV, Chrzanowski DS, Dodson KM. Use of radiesse in combination with restylane for facial augmentation. Arch Facial Plast Surg 2006; 8:92-97.
54. Beer K. A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne or varicella. Dermatol Surg 2007; 33 (Suppl 2):S159-S167.
55. Burgess CM. Treatment of facial asymmetry with poly-L-lactic acid: a case study. Aesthetic Plast Surg 2008 [Epub ahead of print].
56. Ralston JP, Blume JE, Zeitouni NC. Treatment of postoperative soft tissue loss with injectable poly-L-lactic acid. J Drugs Dermatol 2006; 5:1000-1001.
57. Sherman RN. Sculptra: the new three-dimensional filler. Clin Plast Surg 2006; 33:539-550.
58. Lindqvist C, Tveten S, Bondevik BE, Fagrell D. A randomized, evaluator-blind, multicenter comparison of the efficacy and tolerability of Perlane versus Zyplast in the correction of nasolabial folds. Plast Reconstr Surg 2005; 115:282-289.
59. Matti BA, Nicolle FV. Clinical use of Zyplast in correction of age- and disease-related contour deficiencies of the face. Aesthetic Plast Surg 1990; 14:227-234.
60. Elson ML. Clinical assessment of Zyplast Implant: a year of experience for soft tissue contour correction. J Am Acad Dermatol 1988; 18:707-713.
61. Kligman AM, Armstrong RC. Histologic response to intradermal Zyderm and Zyplast (glutaraldehyde cross-linked) collagen in humans. J Dermatol Surg Oncol 1986; 12:351-357.
62. Kaufman MR, Bradley JP, Dickinson B, et al. Autologous fat transfer national consensus survey: trends in techniques for harvest, preparation, and application, and perception of short- and long-term results. Plast Reconstr Surg 2007; 119:323-331.
63. Glasgold M, Lam SM, Glasgold R. Autologous fat grafting for cosmetic enhancement of the perioral region. Facial Plast Surg Clin North Am 2007; 15:461-470; vi.
64. Butterwick KJ, Nootheti PK, Hsu JW, Goldman MP. Autologous fat transfer: an in-depth look at varying concepts and techniques. Facial Plast Surg Clin North Am 2007; 15:99-111; viii.
65. Tzikas TL. Autologous fat grafting for midface rejuvenation. Facial Plast Surg Clin North Am 2006; 14:229-240.
66. Pontius AT, Williams EF 3rd. The evolution of midface rejuvenation: combining the midface-lift and fat transfer. Arch Facial Plast Surg 2006; 8:300-305.
67. Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg 2006; 118:108S-120S.
68. Coleman SR. Facial augmentation with structural fat grafting. Clin Plast Surg 2006; 33:567-577.
69. Moers-Carpi M, Vogt S, Santos BM, et al. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 2007; 33 (Suppl 2):S144-S151.
70. Moers-Carpi MM, Tufet JO. Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for the correction of nasolabial folds: a 12-month, multicenter, prospective, randomized, controlled, split-face trial. Dermatol Surg 2008; 34:210-215.
71. Rohrich RJ, Ghavami A, Crosby MA. The role of hyaluronic acid fillers (Restylane) in facial cosmetic surgery: review and technical considerations. Plast Reconstr Surg 2007; 120:41S-54S.
72. Heffelfinger RN, Blackwell KE, Rawnsley J, Keller GS. A simplified approach to midface aging. Arch Facial Plast Surg 2007; 9:48-55.
73. Gold MH. Use of hyaluronic acid fillers for the treatment of the aging face. Clin Interv Aging 2007; 2:369-376.
74. Ali MJ, Ende K, Maas CS. Perioral rejuvenation and lip augmentation. Facial Plast Surg Clin North Am 2007; 15:491-500; vii.
75. Broder KW, Cohen SR. An overview of permanent and semipermanent fillers. Plast Reconstr Surg 2006; 118:7S-14S.
76. Klein AW, Fagien S. Hyaluronic acid fillers and botulinum toxin type a: rationale for their individual and combined use for injectable facial rejuvenation. Plast Reconstr Surg 2007; 120:81S-88S.
77. Kelly PE. Injectable success: from fillers to Botox. Facial Plast Surg 2007; 23:7-18. (discussion 19-20).
78. McCracken MS, Khan JA, Wulc AE, et al. Hyaluronic acid gel (Restylane) filler for facial rhytids: lessons learned from American Society of Ophthalmic Plastic and Reconstructive Surgery member treatment of 286 patients. Ophthal Plast Reconstr Surg 2006; 22:188-191.
79. Schanz S, Schippert W, Ulmer A, et al. Arterial embolization caused by injection of hyaluronic acid (Restylane). Br J Dermatol 2002; 146:928-929.
80. Shafir R, Amir A, Gur E. Long-term complications of facial injections with Restylane (injectable hyaluronic acid). Plast Reconstr Surg 2000; 106:1215-1216.
81. Graivier MH, Bass LS, Busso M, et al. Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: consensus recommendations. Plast Reconstr Surg 2007; 120:55S-66S.
82. Hanke CW, Higley HR, Jolivette DM, et al. Abscess formation and local necrosis after treatment with Zyderm or Zyplast collagen implant. J Am Acad Dermatol 1991; 25:319-326.
83. Kranendonk S, Obagi S. Autologous fat transfer for periorbital rejuvenation: indications, technique, and complications. Dermatol Surg 2007; 33:572-578.